PT-141 (Bremelanotide): What People Actually Pay and Real Patient Results
HealthRX.com
Reddit users report wide differences in dose and nausea
Key numbers
- 1.75 mgDose of the approved Vyleesi subcutaneous autoinjectorSource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
- 24 hoursLabel limit: no more than one Vyleesi dose in any 24 hoursSource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
- 40.0%Women on Vyleesi who reported nausea, versus 1.3% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
- 0.30 pointsFSFI desire score gain over placebo in study 301, premenopausal women with HSDDSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026
- 18%Treated women who stopped for adverse reactions, versus 2% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
At a glance
- Approved product / Vyleesi 1.75 mg subcutaneous autoinjector, the only FDA-approved bremelanotide product [1][2]
- Approval date / June 21, 2019 (NDA 210557) [1][2]
- Approved for / premenopausal women with acquired, generalized HSDD [1]
- Not indicated for / men, postmenopausal women, or enhancing performance [1]
- FSFI-desire mean change, Vyleesi vs placebo / 0.5 vs 0.2 (study 1) and 0.6 vs 0.2 (study 2), scale 1.2 to 6.0 [1]
- Nausea / 40.0% vs 1.3% on placebo [1]
- Stopped for side effects / 18% vs 2% [1]
- Blood pressure / maximal +6/+3 mmHg; mean +1.9/+1.7 mmHg over 8 days [1]
What is PT-141, and what are you actually buying?
PT-141 is the research name for bremelanotide. The FDA-approved product is Vyleesi, a 1.75 mg subcutaneous prefilled autoinjector approved on June 21, 2019 (NDA 210557) and now held by Cosette Pharmaceuticals [1][2]. It is prescription only and self-injected into the abdomen or thigh [1].
PT-141 sold as a compounded preparation or research-use peptide is not Vyleesi, and it is not an FDA-approved drug [1][4]. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they reach patients [5]. Bremelanotide does not appear on FDA's page of bulk substances that may present significant safety risks, it is not in any category on the agency's bulk-substance lists, and it is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [6][7][8].
The approved use is narrow. Vyleesi is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder: low desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label says it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].
How often it can be used
Vyleesi is a fixed-dose autoinjector dispensed by prescription. The label says not to use more than one dose in 24 hours and does not recommend more than eight doses per month, noting that more frequent dosing increases the risk of focal hyperpigmentation and the time per month when blood pressure is raised [1]. The trial results below concern the 1.75 mg autoinjector. One published study in men, a 2004 trial of intranasal PT-141, used different doses and a different route than Vyleesi [9].
Real patient results: what the trials measured
Two identical phase 3 randomized, double-blind, placebo-controlled trials (NCT02333071 and NCT02338960) randomized 1,267 premenopausal women with HSDD 1:1 to bremelanotide 1.75 mg as needed or placebo for 24 weeks; 1,202 women were in the efficacy analysis, mean age 39 [3]. The coprimary endpoints were the FSFI desire domain score and item 13 of the Female Sexual Distress Scale-Desire/Arousal/Orgasm [3].
Compared with placebo, bremelanotide improved desire scores by 0.30 points in study 301, 0.42 in study 302 and 0.35 across both studies, all statistically significant (P<0.001) [3]. The label's own table shows mean FSFI-desire changes of 0.5 versus 0.2 in study 1 and 0.6 versus 0.2 in study 2 [1]. Compared with placebo, distress about low desire decreased by 0.37 points in study 301, 0.29 in study 302 and 0.33 across both studies (P<0.001, P=0.005 and P<0.001) [3].
One result gets lost in most summaries: the trials found no significant difference between bremelanotide and placebo in the number of satisfying sexual events [3].
How many women stayed on it
More women left the double-blind phase early on bremelanotide than on placebo: 40% versus 13% in study 1 and 39% versus 25% in study 2 [1]. The label also reports an exploratory analysis of the women who completed the 24 weeks and improved from baseline [1]. Across the pooled phase 3 trials, 18% of treated women discontinued for adverse reactions versus 2% on placebo [1].
In the 52-week open-label extension, 684 of the 856 women who finished the core phase enrolled and 272 completed it; the most common drug-related events were nausea (40.4%), flushing (20.6%) and headache (12.0%), and those analyses were descriptive with no placebo group [10].
What people on Reddit report
Anecdotes from Reddit users describing their own dosing, nausea and results. These are personal reports, not trial data, and they vary widely.
You're going to have to try it several times before you can get a consistent dose. From what I read because your body kind of slightly adapts to it. And from what I've seen it's not consistent.Read the source discussion
And I never get any nausea or other bad side effects from PT-141.Read the source discussion
What the label says to expect
Nausea was reported by 40.0% of women on Vyleesi versus 1.3% on placebo; 13% needed anti-nausea medicine and 8% stopped the trials because of it [1]. It was most common after the first dose, reported in 21% of patients, and fell to about 3% after later doses [1]. In a phase 4 single-dose study of 228 healthy women, taking 8 mg of oral ondansetron 30 minutes before the injection did not reduce nausea, and the label does not recommend it [1].
Other common reactions, Vyleesi versus placebo: flushing 20.3% versus 0.3%, injection site reactions 13.2% versus 8.4%, headache 11.3% versus 1.9%, vomiting 4.8% versus 0.2% [1]. Serious adverse reactions were reported in 1.1% of treated women versus 0.5% on placebo [1].
Each dose transiently raises blood pressure and lowers heart rate. Maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate down up to 5 beats per minute; readings usually returned to baseline within 12 hours [1]. In an ambulatory study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart rate decrease of 0.5 beats per minute [1]. Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease and is not recommended for patients at high risk of cardiovascular disease [1].
Focal hyperpigmentation, including the face, gums and breasts, was reported by 1% of women taking up to 8 doses a month versus none on placebo [1]. In a separate study, 38% developed it after daily dosing for 8 days and a further 14% after 8 more consecutive days; risk is higher with darker skin and with daily dosing, resolution was not confirmed in everyone, and the label says to consider discontinuing if it develops [1].
One case of acute hepatitis occurred in the open-label extension after 10 doses, with transaminases over 40 times the upper limit of normal; another cause was not identified and a role for Vyleesi could not be excluded [1]. The label says to use effective contraception and to stop Vyleesi if pregnancy is suspected; in dogs, fetal harm occurred at exposures at least 16 times the human dose by AUC [1]. FDA approved a labeling supplement on October 22, 2026 that updates the pregnancy and specific-populations section, and the new text was not yet in DailyMed on October 28, 2026 [11].
The label's dosing is 1.75 mg at least 45 minutes before anticipated sexual activity, no more than one dose in 24 hours, no more than 8 doses a month, and stopping after 8 weeks if there is no improvement; how long a single dose's effect lasts is unknown [1]. The label says to avoid Vyleesi with oral naltrexone products for alcohol or opioid addiction, and with oral drugs that depend on threshold blood levels, such as antibiotics [1].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Questions worth asking
Frequently asked questions
What does PT-141 cost?
Does bremelanotide actually improve desire?
How bad is the nausea?
Can men use PT-141?
How long does one dose last?
Can it be taken with other medicines?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
How long does it take for PT-141 to kick in Reddit?
The label says to use a dose at least 45 minutes before anticipated sexual activity, and no more than one dose in 24 hours. How long a single dose's effect lasts is unknown, so no longer timeline is given.
Where can I buy bremelanotide PT-141?
Vyleesi, the FDA-approved form, is prescription only and self-injected into the abdomen or thigh. PT-141 sold as a compounded preparation or research-use peptide is not Vyleesi and is not an FDA-approved drug. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they reach patients.
References
Show all 13 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
- Official web page.
- Human Drug Compounding Laws | FDA.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-9.
- Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917.
- U.S. Food and Drug Administration.
- Reddit participants. Does PT-141 increase the libido? (r/Biohacking). Accessed 2026-11-11.
- Reddit participants. PT-141 Experience - it absolutely works (r/erectiledysfunction). Accessed 2026-11-11.